New genetic sequencing lab creates 'tipping point' for personalised cancer ...
Join Scoop.it for Free
Share ideas that matter on the social web and experience
the benefits of curating the world's best content.
I don't have a Facebook, a Twitter or a LinkedIn account
Already have an account: Login
Sharing relevant articles on advancements in personalized medicine
Curated by
Brian Shields
 Your new post is loading...
Scoop.it!
No comment yet.
Sign up to comment
Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
GE Healthcare Launches its First “Next-Generation” Sequencing Assay http://t.co/1JUJWflRPr Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Science of genome-sequencing has rocketed forward in 10 years Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Medical School Establishes Biomarker Discovery Center Newswise (press release) Newswise — STRATFORD, NJ – Following recent discoveries by its researchers that could significantly change the diagnosis and treatment of a number of diseases, the... Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
CHARLES BANKHEAD: I'm Charles Bankhead of MedPage Today, and this is Expert Commentary, Non-Small Cell Lung Cancer. My guest is Dr. Lecia Sequist of the Massachusetts General Hospital. She is a thoracic medical oncologist at the MGH Cancer Center and is also assistant professor of medicine at Harvard. Thank you for joining us... Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
MRI scans of migraine sufferers have revealed that the intense, throbbing headaches they suffer are related to brain abnormalities, some of which are present at birth and others that develop over time, according to a study published online March 26... Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Fifty years ago, oncologists relied upon the clinical exam to follow breast cancer patients with metastatic disease. Patients were treated with chemotherapy, and then the physicians waited for symptoms to return before deciding on the next treatment course. Some patients could go months or even years without symptoms, but during this time they played a waiting game. Technology did not yet exist to allow physicians to detect cancer progression in the absence of overt clinical clues. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
THE first publication on the use of WA’s Lotterywest Next-Gen sequencing platform in a human context has been released, revealing two novel genetic aberrations that lead to the onset of a devastating neuromuscular disease in utero. Equally significant is proof that the latest sequencing technology can be used successfully and cost-effectively in gene discovery and diagnosis of rare disease cases. Neuromuscular disease experts, Dr Gina Ravenscroft and Professor Nigel Laing from the Western Australian Institute for Medical Research (WAIMR), and clinicians and pathologists in Western and South Australia, have identified two new variants of a gene, known to regulate glycogen availability for muscle development. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
International Journal of Surgical Oncology is a peer-reviewed, open access journal that publishes original research articles, review articles, and clinical studies in all areas of surgical oncology. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Emory receives NINDS grant for biomarker research on Parkinson's
Brian Shields's insight:
Some exciting news coming out of my alma mater, Emory University. The goal of this research is to "achieve a better prognosis for patients by identifying neuro-degeneration earlier", according to F. DuBois Bowman, PhD, the leader of the grant initiative. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
ORLANDO—CT texture analysis of primary tumors may be a potential imaging biomarker in localized esophageal cancer following neoadjuvant chemotherapy, according to research being presented at the 2013 Cancer ...
Brian Shields's insight:
Important info for a difficult to treat cancer, esophageal cancer. The use of imaging may help physicians determine the best treatment choice for patients. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
RT @EricTopol: Genomics at Your Fingertips http://t.co/iehVcVfP by @drkevincampbell HT @cyphergenomics #CDoM
Brian Shields's insight:
Interesting article on the possible future development of sequencing in the primary care office. The article builds off a new technology reported by Anne Eisenberg in a recent NY Times article. This technology from a company called Knome, allows a single Lab or office to sequence a person's genome. The technology costs about $125,000. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
DAI provides potential imaging biomarker to indicate brain tumor response to RT Medical Xpress Diffusion abnormality index (DAI) shows promise as an imaging biomarker to measure brain tumor response to radiation therapy, according to research being...
Brian Shields's insight:
This is a positive step forward in providing patients with more accurate treatment decisions when Radiation therapy is used to treat brain tumors. This Biomarker is a new diffusion index, DAI, which could potentially indicate post-treatment tumor response. "While this review included a small number of patients, the data demonstrate that DAI may be a good biomarker to predict brain tumor response," said lead study author Reza Farjam, a PhD candidate in biomedical engineering focused on cancer functional imaging at the University of Michigan in Ann Arbor, Mich. "Further study of this method is needed to improve early prediction of tumor response to radiation therapy and to help us provide brain cancer patients with more accurate information about their treatment progress." Read more at: http://medicalxpress.com/news/2013-02-dai-potential-imaging-biomarker-brain.html#jCp Delete the scoop?
Are you sure you want to delete this scoop?
Yes
|
Scoop.it!
Bioscience Technology New Schizophrenia Diagnostic Method Found - Bioscience Technology Bioscience Technology Researchers have discovered a method for physical diagnosis of schizophrenia by collecting tissue from the nose Schizophrenia, a...
Brian Shields's insight:
Very interesting development in psychiatry...scientists from Tel Aviv University and Johns Hopkins identify olfactory neurons that may possibly be used for early diagnosis of schizophrenia. It is not clear yet whether this biomarker is apparent before symptoms appear. 
Florence Piron's comment,
May 3, 8:32 AM
Don't you find it a strange and very limited method to work on a very complex disease with strong social and psychological components??
Brian Shields's comment,
May 23, 10:26 PM
Yes, a very strange development for a complex disease. However, scientists are doing a nice job now of monitoring the signals that our body produces to better diagnose and treat these difficult diseases. Perhaps scientists have realized that treating schizophrenia after it has already been diagnosed is a difficult path to follow. Perhaps early detection is the path toward a better treatment paradigm?
Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
NanoVelcro Chip device captures and isolates potentially high-risk cancer cells
Brian Shields's insight:
A great advancement may be on the horizon for the treatment of patients with Prostate Cancer. The use of circulating tumor cells or "liquid biopsies" may prevent the need for painful and invasive procedures to obtain biopsy tissue. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
The discovery of activating mutations in EGFR radically changed the treatment options for these patients, and, indeed, treatment of advanced stage patients with EGFR-mutated tumors with erlotinib (in the US) is now front-line ... 
Raj Desai, Ph.D.,'s curator insight,
April 1, 6:57 PM
We still need to go extra mile to cover all bases.
Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Elevated levels of Cyclin D1b could function as a novel biomarker of lethal metastatic disease in prostate cancer patients, according to a pre-clinical study published ahead of print on December 21...Read the whole entry... »... Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Although the presence of an EGFR mutation is a predictive marker for response to EGFR tyrosine kinase inhibitor therapy in patients with non-small cell lung cancer, the mutation is not a prognostic factor. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Multiple sclerosis (MS) is a central nervous system (CNS) disorder characterised by demyelination and neurodegeneration. Although hallmarks of recovery (remyelination and repair) have been documented in early MS, the regenerative capacity of the adult CNS per se remains uncertain with the wide held belief that it is either limited or non-existent. The neural cell adhesion molecule (NCAM) is a cell adhesion molecule that has been widely implicated in axonal outgrowth, guidance and fasciculation. Here, we used in vitro and in vivo studies in MS to investigate the role of NCAM in disease progression. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
A new diagnostic test that uses metabolomic analysis may be a safe and easy screening method to detect pancreatic cancer, researchers in Japan said. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Lung cancer is a tricky disease and there is a graveyard littered with lung cancer drugs that failed in clinical trial.Targeted approaches like Xalkori from Pfizer (PFE) and Tarceva from Roche (RHHBY.OB) work for small segmen...
Brian Shields's insight:
Very good insight on the current targeted options available for lung cancer patients and the promising products in development such as Dacomitinib and Reolysin. The article notes that the molecular testing rate in Lung Cancer is now 60%, a growth from 10% at the launch of Xalkori. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
Heidi Rehm has been using disease-targeted gene panels to diagnose patients in her clinical molecular genetics practice for a decade. Having adopted next-generation sequencing approaches two years ago, and whole-genome and whole-exome sequencing for some patients in the past year, she is a pioneer in applying genomics in the clinic.
Brian Shields's insight:
Very good discussion on the current impact that genetic and genomic sequencing are having on clinical decisions, and a look into the future when genome analysis is much more cost effective. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
IBM is turning Watson loose on lung cancer, offering up a cloud-based service designed to let doctors from around the country find the best-possible treatments for their patients. Via Alex Butler
Brian Shields's insight:
Very exciting to see the leaders in tech partner with the leaders in cancer care. I believe the next revolution in medicine will be driven by technology and the front line health care and research institutes. Aggregating and utilizing data intelligently will help clinicians and reseachers better provide care to the community. The lines between research trials and the standards of care may gradually blur as new technology driven treatment strategies emerge. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
Scoop.it!
OncLive BATTLE-2: Next-Generation of Biomarker-Driven Trials OncLive While the number of known mutations and matching targeted agents is relatively limited at present, clinical trials are being designed to identify effective therapies for specific...
Brian Shields's insight:
The next-generation of clinical trials...Powerful quote in this article from Dr. Roy Herbst: Herbst: Absolutely. I think it’s essential. If you don’t let the biology drive the treatment, everything is empiricism and it is going to have a very low chance of hitting the mark. So absolutely, as Dr Wistuba said, treat patients the best you can in real time, but also learn, discover, identify new markers. This trial uses biomarkers to guide decisions, thereby providing patients with the best possible treatment arm, despite randomization. Delete the scoop?
Are you sure you want to delete this scoop?
Yes
|
Sarah Cannon and the UCL Cancer Institute of the UK establish a genetic sequencing platform for cancer patients focused on identifying driver mutations with "actionable" available treatments. This platform also requires less tissue for the testing and may be performed at a lower cost than traditional gene sequencing.